Citation Impact
Citing Papers
Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C
2007
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis
2010
Intensive versus Conventional Glucose Control in Critically Ill Patients
2009 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) Study: statistical analysis plan
2009
Safety of Drotrecogin Alfa (Activated) in Surgical Patients with Severe Sepsis
2004
Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome
2006
Reducing mortality in sepsis: new directions.
2002
Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock
2008
Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients<subtitle>A Randomized Trial</subtitle>
2009 Standout
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial
2007
Sepsis biomarkers: a review
2010 Standout
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
1998 Standout
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
2020 Standout
Melioidosis
2018 Standout
Food, livestock production, energy, climate change, and health
2007 Standout
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
2007 StandoutNature
'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage
2007
Promoting Global Research Excellence in Severe Sepsis (PROGRESS): Lessons from an International Sepsis Registry
2009
Understanding the Inflammatory Cytokine Response in Pneumonia and Sepsis
2007
Drotrecogin Alfa (Activated) in Adults with Septic Shock
2012 Standout
Management of Sepsis
2006
Before–after study of a standardized hospital order set for the management of septic shock*
2006
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
2015 Standout
New Antithrombotic Drugs
2012
Host–pathogen interactions in sepsis
2007
Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US)
2004
Pathophysiology of Sepsis
2007
Sepsis and Septic Shock: A History
2009
Delirium as a Predictor of Mortality in Mechanically Ventilated Patients in the Intensive Care Unit
2004 Standout
Cardiovascular implications from untreated human immunodeficiency virus infection
2011
Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis
2007
Melioidosis
2012 Standout
Group V Phospholipase A2 Induces Leukotriene Biosynthesis in Human Neutrophils through the Activation of Group IVA Phospholipase A2
2002
Identification of the Phosphorylation Sites of Cytosolic Phospholipase A2 in Agonist-stimulated Human Platelets and HeLa Cells
1998
Management of Sepsis
2011
Activated protein C (Xigris®) treatment in sepsis: a drug in trouble
2006
Inhibition of Ca2+‐independent phospholipase A2 by bromoenol lactone attenuates prostaglandin generation induced by interleukin‐1β and dibutyryl cAMP in rat mesangial cells
1998
Inflammation and coagulation
2010
Severe Sepsis and Septic Shock
2013 Standout
Inhibition of MAP kinase kinase (MEK) blocks endothelial PGI2 release but has no effect on von Willebrand factor secretion or E‐selectin expression
1996
Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice
2017 Standout
A Novel Cytosolic Calcium-independent Phospholipase A2 Contains Eight Ankyrin Motifs
1997
New Structural Scaffolds for Centrally Acting Oxime Reactivators of Phosphylated Cholinesterases
2011 StandoutNobel
High‐mobility group box 1 protein promotes development of microvascular thrombosis in rats
2006
Thrombin signalling and protease-activated receptors
2000 StandoutNature
p38 Mitogen-activated Protein Kinase Phosphorylates Cytosolic Phospholipase A2 (cPLA2) in Thrombin-stimulated Platelets
1996
Protease-activated receptor 3 is a second thrombin receptor in humans
1997 Nature
Human recombinant activated protein C for severe sepsis
2012
Peptidomimetic design
1998
The ATP-gated P2X1 Receptor Plays a Pivotal Role in Activation of Aspirin-treated Platelets by Thrombin and Epinephrine
2008 StandoutNobel
Sepsis and septic shock
2018 Standout
From evidence to clinical practice: Effective implementation of therapeutic hypothermia to improve patient outcome after cardiac arrest*
2006
Hydrocortisone Therapy for Patients with Septic Shock
2008 Standout
A dual thrombin receptor system for platelet activation
1998 Nature
Mitogenic Signaling via G Protein-Coupled Receptors
1996 StandoutNobel
Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated)
2007
Sepsis-Associated Myocardial Dysfunction
2006
Thrombin Induces Activation of p38 MAP Kinase in Human Platelets
1995
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control
2012
Emerging drugs for the treatment of sepsis
2016
High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*
2006
Bundled care for septic shock: An analysis of clinical trials*
2010
Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*
2009
Current treatment of severe sepsis
2006
Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation
2013 Standout
Outcomes in severe sepsis and patients with septic shock: Pathogen species and infection sites are not associated with mortality*
2011
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
2009 Standout
Problems of stopping trials early
2012
The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis *
2004
Variation in critical care services across North America and Western Europe*
2008
Integrins
2002 Standout
Properties and Regulation of Cytosolic Phospholipase A2
1997
Prevalence and Significance of Coagulation Abnormalities in Community-Acquired Pneumonia
2009
Phospholipase A2 enzymes
2002
Painful Diabetic Polyneuropathy
2011
Hypertonic Induction of Aquaporin-5 Expression through an ERK-dependent Pathway
2000 StandoutNobel
Protein–protein interactions as targets for small molecule drug discovery
2006
Identification of Phosphorylation Sites of Human 85-kDa Cytosolic Phospholipase A2 Expressed in Insect Cells and Present in Human Monocytes
1996
Climate change and human health: present and future risks
2006 Standout
Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)
2003
Assessment of Clinical Criteria for Sepsis
2016 Standout
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
2016 Standout
Inhibition of mitogen-activated protein kinase kinase does not impair primary activation of human platelets
1996
Bacterial lipopolysaccharides and innate immunity.
2001
Synthesis of Pyridine and Dihydropyridine Derivatives by Regio- and Stereoselective Addition toN-Activated Pyridines
2012 Standout
Role for p38 Mitogen-activated Protein Kinase in Platelet Aggregation Caused by Collagen or a Thromboxane Analogue
1996
Part 9: Post–Cardiac Arrest Care
2010 Standout
Palladium-Catalyzed Transformations of Alkyl C–H Bonds
2016 Standout
Different Effects of Thrombin Receptor Activation on Endothelium and Smooth Muscle Cells of Human Coronary Bypass Vessels
1997
Invasive Candidiasis
2015 Standout
Aryl−Aryl Bond Formation by Transition-Metal-Catalyzed Direct Arylation
2007 Standout
1,4‐Dihydropyridines: Effects of Chirality and Conformation on the Calcium Antagonist and Calcium Agonist Activities
1991
A Field Guide to Foldamers
2001 Standout
Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality
2005 Standout
Enantioselective palladium(0)-catalyzed intramolecular cyclopropane functionalization: access to dihydroquinolones, dihydroisoquinolones and the BMS-791325 ring system
2015
P2X1-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen
2002
Aortocoronary Saphenous Vein Graft Disease
1998 Standout
Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure
2011 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII
2013 StandoutNobel
Right Ventricular Function in Cardiovascular Disease, Part I
2008 Standout
Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012
2014
Lipopolysaccharide Endotoxins
2002 Standout
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
2015 Standout
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units
2004
Developing a New Definition and Assessing New Clinical Criteria for Septic Shock
2016 Standout
Platelet Glycoprotein IIb-IIIa Antagonists as Prototypical Integrin Blockers: Novel Parenteral and Potential Oral Antithrombotic Agents
2000
Sepsis: Multiple Abnormalities, Heterogeneous Responses, and Evolving Understanding
2013
Regioselective palladium-catalyzed phenylation of ethyl 4-oxazolecarboxylate
2005
N-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide as a New Scaffold that Provides Rapid Access to Antimicrotubule Agents: Synthesis and Evaluation of Antiproliferative Activity Against Select Cancer Cell Lines
2010
Works of Barbara G. Utterback being referenced
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]
2004
International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety
2007
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*
2003
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial
2003
Differential Activation of Cytosolic Phospholipase A2 (cPLA2) by Thrombin and Thrombin Receptor Agonist Peptide in Human Platelets. EVIDENCE FOR ACTIVATION OF cPLA2 INDEPENDENT OF THE MITOGEN-ACTIVATED PROTEIN KINASES ERK1/2
1995
Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications
2000
Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei
2005
ENHANCE: Results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis*
2006
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
2005
Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials
2010
Non-Peptide RGD Surrogates Which Mimic a Gly-Asp β-Turn: Potent Antagonists of Platelet Glycoprotein IIb−IIIa
1997
Dihydroisoquinolone RGD mimics. Exploration of the aspartate isostere
1997
LY249933
1989
Development of Dual-Acting Agents for Thromboxane Receptor Antagonism and Thromboxane Synthase Inhibition. 3. Synthesis and Biological Activities of Oxazolecarboxamide-Substituted ω-Phenyl-ω-(3-pyridyl)alkenoic Acid Derivatives and Related Compounds
1998